First Time Loading...
G

Gentian Diagnostics ASA
OSE:GENT

Watchlist Manager
Gentian Diagnostics ASA
OSE:GENT
Watchlist
Price: 36.8 NOK -2.13%
Updated: Apr 29, 2024

Wall Street
Price Targets

GENT Price Targets Summary
Gentian Diagnostics ASA

Wall Street analysts forecast GENT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GENT is 55.08 NOK with a low forecast of 54.54 NOK and a high forecast of 56.7 NOK.

Lowest
Price Target
54.54 NOK
48% Upside
Average
Price Target
55.08 NOK
50% Upside
Highest
Price Target
56.7 NOK
54% Upside
Gentian Diagnostics ASA Competitors:
Price Targets
3593
Hogy Medical Co Ltd
2% Downside
HARTA
Hartalega Holdings Bhd
7% Downside
POLYMED
Poly Medicure Ltd
4% Downside
AP4
Riverstone Holdings Ltd
3% Upside
NEOG
Neogen Corp
43% Upside
MMSI
Merit Medical Systems Inc
29% Upside
600529
Shandong Pharmaceutical Glass Co Ltd
22% Upside
603658
Autobio Diagnostics Co Ltd
12% Upside

Revenue
Forecast

Revenue Estimate
Gentian Diagnostics ASA

For the last 7 years the compound annual growth rate for Gentian Diagnostics ASA's revenue is 28%. The projected CAGR for the next 2 years is 24%.

28%
Past Growth
24%
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Gentian Diagnostics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Net Income
Forecast

Net Income Estimate
Gentian Diagnostics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GENT's stock price target?
Price Target
55.08 NOK

According to Wall Street analysts, the average 1-year price target for GENT is 55.08 NOK with a low forecast of 54.54 NOK and a high forecast of 56.7 NOK.

What is Gentian Diagnostics ASA's Revenue forecast?
Projected CAGR
24%

For the last 7 years the compound annual growth rate for Gentian Diagnostics ASA's revenue is 28%. The projected CAGR for the next 2 years is 24%.